Physician

Anthony J. Olszanski, M.D.

According to 2025 Medicare claims, Anthony Olszanski, M.D. (NPI: 1447483433) practices hematopoietic cell transplantation and cellular therapy in the Montgomery County-Bucks County-Chester County, PA market, with the plurality of this provider's patient population coming from Bucks, PA. This provider's primary affiliated billing organization is TEMPLE FACULTY PRACTICE PLAN, INC (NPI: 1417430166; TIN: 831002191) and primary practice location at 19111-2434.

Olszanski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 112 traditional Medicare patients, billed 355 HCPCS/CPT codes, and received $31,437 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 169 prescription claims across 46 beneficiaries totaling $779,630 in drug costs, led by Xalkori (Crizotinib). 2018 DME data shows 150 claims. Open Payments data shows 147 records totaling $1,141,590. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $160,614 to $779,630. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	122	390	$31,744
2016	109	391	$30,725
2017	85	321	$26,412
2018	106	566	$44,652
2019	130	602	$42,337
2020	136	534	$34,950
2021	140	450	$37,802
2022	133	423	$38,367
2023	142	441	$42,651
2024	112	355	$31,437

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	75	401	$160,614
2016	62	348	$195,265
2017	39	154	$64,643
2018	34	158	$171,862
2019	38	176	$197,573
2020	47	216	$185,074
2021	39	160	$326,273
2022	46	180	$737,084
2023	38	159	$1,071,825
2024	46	169	$779,630

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	150	$93,296
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	17	17	$130
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	63	139	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	66	146	$73
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	11	18	$25

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xalkori	Crizotinib	11	330	$230,913
Levothyroxine Sodium	Levothyroxine Sodium	12	480	$63
Prednisone	Prednisone	20	498	$60

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$3,250	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	135	$1,138,340	Takeda Pharmaceuticals U.S.A., Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anthony J. Olszanski, M.D.?

Tedicare shows public-source Medicare data for Anthony J. Olszanski, M.D. (NPI 1447483433), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anthony J. Olszanski, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anthony J. Olszanski, M.D.?

Anthony J. Olszanski, M.D. is linked to TEMPLE FACULTY PRACTICE PLAN, INC (billing NPI 1417430166) in the available physician profile data.

Does Anthony J. Olszanski, M.D. have Open Payments data?

Anthony J. Olszanski, M.D. has 147 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.